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Thiosulfate induces 
urinary calcium loss 
and reduces metastatic 
calcification in aorta 
and kidney
Accelerated vascular calcification is a 
severe complication of chronic kidney 
disease, contributing to high morbid­
ity and mortality in patients undergo­
ing renal replacement therapy. While 
control of phosphate calcium and para­
thyroid hormone levels is essential to 
preventing or improving calcification, 
there is a real need for new therapies. 
Recent studies have suggested that treat­
ment with sodium thiosulfate might be 
of benefit in this condition. When Pasch 
et al. treated uremic rats with this rea­
gent, they found that the animals had 
less aortic and renal calcification than 
control uremic animals. Concomitantly, 
an increase in urine calcium excretion 
and a transient fall in serum calcium 
were seen. Further, while thiosulfate 
induced metabolic acidosis in the ure­
mic animals, it lowered bone strength, 
and thus prevented vascular calcifica­
tion. How could thiosulfate produce 
all of these disparate effects? One pos­
sibility is that increased calcium excre­
tion reduced calcification, perhaps by a 
mechanism similar to chelation. If so, 
then the risk of long­term calcium loss 
will have to be weighed against that 
of metastatic calcification when such 
therapies are recommended in humans. 
See page 1444.
Statins, C-reactive 
protein, and the risk 
of poor outcome in 
hemodialysis patients
Although statins were developed to 
reduce cholesterol, they have been found 
to have anti­inflammatory action largely 
due to their lowering of lipid signaling 
intermediates. A proinflammatory state 
is often associated with elevated levels 
of C­reactive protein. As they report in 
this issue, Krane et al. studied more than 
one thousand patients with type 2 diabe­
tes mellitus on hemodialysis who were 
given statins. In this post hoc analysis, the 
authors found that atorvastatin had no 
significant effect on the risk of compos­
ite vascular end point, stroke, or death 
relative to placebo. When C­reactive pro­
tein was measured twice, an increase in 
its level was found to be associated with 
an increase in the incidence of stroke 
or sudden death. Hence, in hemodialy­
sis patients it appears that a statin does 
not improve outcomes in hemodialysis 
patients. Worth noting, the proinflam­
matory state as measured by C­reactive 
protein has been associated with poor 
outcome in numerous prior studies. 
See page 1461.
Urinary fractalkine in 
acute graft rejection
Allograft rejection is mediated by mono­
nuclear cells, which invade the graft in 
response to secretion of chemokines by a 
variety of cell types in the kidney. Identi­
fication of the responsible chemokines is 
necessary for understanding of the pro­
cess of rejection, as well as prediction of 
the outcome and provision of specific 
therapeutic intervention. Peng et al. 
present a new study in which they meas­
ured the excretion of a large number of 
chemokines in 215 allograft recipients 
and 80 normal controls. One­third of the 
recipients had acute rejection episodes 
and higher levels of all of the chemo­
kines tested as compared with those 
with chronic rejection or normal con­
trol subjects. However, when the authors 
attempted to test which of the cytokines 
differentiated among the causes of acute 
kidney malfunction, they found that 
only fractalkine differentiated between 
rejection and acute tubular necrosis. 
The level of urinary fractalkine was also 
useful in predicting graft loss. This new 
biomarker may be useful in the diagno­
sis of acute rejection and lead to further 
studies on the role of this chemokine 
in the pathogenesis of acute rejection. 
See page 1454.
